BRIEF-Sage Therapeutics Submits New Drug Application To U.S. FDA For Intravenous Brexanolone In The Treatment Of Postpartum Depression
April 23, 2018 at 07:14 AM EDT
* SAGE THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR INTRAVENOUS BREXANOLONE IN THE TREATMENT OF POSTPARTUM DEPRESSION
